INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults.

Autor: Talleur AC; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee. Electronic address: atalleur@stjude.org., Fabrizio VA; Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplant, Children's Hospital Colorado/University of Colorado Anschutz, Aurora, Colorado., Aplenc R; Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Grupp SA; Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Mackall C; Department of Pediatrics, Department of Medicine, Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford University, Stanford, California., Majzner R; Dana-Farber Cancer Institute, Boston, Massachusetts., Nguyen R; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Rouce R; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, Texas., Moskop A; Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, Wisconsin., McNerney KO; Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Jun; Vol. 30 (6), pp. 565-579. Date of Electronic Publication: 2024 Apr 07.

c-Jun overexpression in CAR T cells induces exhaustion resistance.

Autor: Lynn RC; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.; Lyell Immunopharma, South San Francisco, CA, USA., Weber EW; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Sotillo E; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Gennert D; Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA., Xu P; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Good Z; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.; Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Anbunathan H; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Lattin J; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Jones R; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Tieu V; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Nagaraja S; Department of Neurology, Stanford University, Stanford, CA, USA., Granja J; Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA., de Bourcy CFA; Departments of Bioengineering and Applied Physics, Stanford University, Stanford, CA, USA.; Chan Zuckerberg Initiative, San Francisco, CA, USA., Majzner R; Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA., Satpathy AT; Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Quake SR; Departments of Bioengineering and Applied Physics, Stanford University, Stanford, CA, USA.; Chan Zuckerberg Biohub, San Francisco, CA, USA., Monje M; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.; Department of Neurology, Stanford University, Stanford, CA, USA.; Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA., Chang HY; Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.; Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA., Mackall CL; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. cmackall@stanford.edu.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. cmackall@stanford.edu.; Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. cmackall@stanford.edu.; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. cmackall@stanford.edu.

Publikováno v: Nature [Nature] 2019 Dec; Vol. 576 (7786), pp. 293-300. Date of Electronic Publication: 2019 Dec 04.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PD1CD28 chimeric molecule enhances EGFRvⅢ specific CAR-T cells in xenograft experiments in mouse models.

Autor: Chen, Wanqiong¹ (AUTHOR), Xian, Na^2,3 (AUTHOR), Zhao, Ningning⁴ (AUTHOR), Zhang, Qiong⁵ (AUTHOR), Xu, Yunlu⁶ (AUTHOR) xuyunlu3578@fjmu.edu.cn

Publikováno v: PLoS ONE. 10/01/2024, Vol. 19 Issue 10, p1-14. 14p.

Dual targeting chimeric antigen receptor cells enhance antitumour activity by overcoming T cell exhaustion in pancreatic cancer.

Autor: Ruixin S; State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.; Department of Laboratory Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China., Yifan L; State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China., Yansha S; State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China., Min Z; State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China., Yiwei D; State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China., Xiaoli H; CARsgen Therapeutics, Shanghai, China., Bizhi S; State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.; CARsgen Therapeutics, Shanghai, China., Hua J; State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.; CARsgen Therapeutics, Shanghai, China., Zonghai L; State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.; CARsgen Therapeutics, Shanghai, China.

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2024 Nov; Vol. 181 (22), pp. 4628-4646. Date of Electronic Publication: 2024 Aug 11.